Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Pragmatica-Lung Study, with fewer and simpler eligibility criteria, will test whether Cyramza plus Keytruda improves survival.
Ramucirumab slowed disease progression more than a placebo when added to erlotinib.
There are now five targeted therapies for the most common type of liver cancer.
Twice as many patients were alive 18 months after starting treatment.
Recommendations now include multiple systemic medications in addition to surgery and local therapies.
Study shows VEGF inhibitor is effective for patients with a biomarker of poor prognosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.